Washington: Researchers have claimed that a combination of two FDA-approved osteoporosis drugs having different mechanisms of action increases bone density better than treatment with either drug alone.The Massachusetts General Hospital (MGH) investigators found that a treatment that combined denosumab (Prolia) and teriparatide (Forteo) was superior to single-agent treatment in a 12-month trial in women with postmenopausal osteoporosis.
Tejas closer to induction into IAF
No plans to drop charges against Khobragade: US
`Dhoom 3` audience verdict
Lieutenant Governor Najeeb Jung recommends President`s rule in Delhi